BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Clay A, Hearle P, Schadt K, Lynch DR. New developments in pharmacotherapy for Friedreich ataxia. Expert Opin Pharmacother 2019;20:1855-67. [PMID: 31311349 DOI: 10.1080/14656566.2019.1639671] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Hanaford AR, Cho YJ, Nakai H. AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives. Orphanet J Rare Dis 2022;17:217. [PMID: 35668433 DOI: 10.1186/s13023-022-02324-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Monfort B, Want K, Gervason S, D’autréaux B. Recent Advances in the Elucidation of Frataxin Biochemical Function Open Novel Perspectives for the Treatment of Friedreich’s Ataxia. Front Neurosci 2022;16:838335. [DOI: 10.3389/fnins.2022.838335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rufini A, Malisan F, Condò I, Testi R. Drug Repositioning in Friedreich Ataxia. Front Neurosci 2022;16:814445. [DOI: 10.3389/fnins.2022.814445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Maio N, Rouault TA. Mammalian iron sulfur cluster biogenesis and human diseases. IUBMB Life. [DOI: 10.1002/iub.2597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Shah S, Dooms MM, Amaral-Garcia S, Igoillo-Esteve M. Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders. Front Pharmacol 2021;12:768023. [PMID: 34992533 DOI: 10.3389/fphar.2021.768023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Perlman S; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Emerging Therapies in Friedreich's Ataxia: A Review. Neurology 2022;18:32. [DOI: 10.17925/usn.2022.18.1.32] [Reference Citation Analysis]
7 He PK, Gao YY, Lyu FJ, Chen JN, Zhang YH, Nie K, Zhang QX, Huang R, Duan QR, Guo ML, Liu ZH, Huang HL, Ma GX, Wang LJ, Wang LM. Idebenone-Activating Autophagic Degradation of α-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson's Disease: A Network Pharmacological Approach. Evid Based Complement Alternat Med 2021;2021:8548380. [PMID: 34567221 DOI: 10.1155/2021/8548380] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Villa C, Legato M, Umbach A, Riganti C, Jones R, Martini B, Boido M, Medana C, Facchinetti I, Barni D, Pinto M, Arguello T, Belicchi M, Fagiolari G, Liaci C, Moggio M, Ruffo R, Moraes CT, Monguzzi A, Merlo GR, Torrente Y. Treatment with ROS detoxifying gold quantum clusters alleviates the functional decline in a mouse model of Friedreich ataxia. Sci Transl Med 2021;13:eabe1633. [PMID: 34408077 DOI: 10.1126/scitranslmed.abe1633] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Lynch DR, Schadt K, Kichula E, McCormack S, Lin KY. Friedreich Ataxia: Multidisciplinary Clinical Care. J Multidiscip Healthc 2021;14:1645-58. [PMID: 34234452 DOI: 10.2147/JMDH.S292945] [Reference Citation Analysis]
10 Wang H, Norton J, Xu L, DeMartinis N, Sen R, Shah A, Farmer J, Lynch D. Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia. Ann Clin Transl Neurol 2021;8:1343-52. [PMID: 34018342 DOI: 10.1002/acn3.51373] [Reference Citation Analysis]
11 Lynch DR, Farmer G. Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions. Neuronal Signal 2021;5:NS20200093. [PMID: 34046211 DOI: 10.1042/NS20200093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Corben LA, Nguyen KD, Pathirana PN, Horne MK, Szmulewicz DJ, Roberts M, Delatycki MB. Developing an Instrumented Measure of Upper Limb Function in Friedreich Ataxia. Cerebellum 2021;20:430-8. [PMID: 33400236 DOI: 10.1007/s12311-020-01228-1] [Reference Citation Analysis]
13 Vavla M, Arrigoni F, Toschi N, Peruzzo D, D'Angelo MG, Gandossini S, Russo A, Diella E, Tirelli S, Salati R, Rufini A, Condo I, Testi R, Martinuzzi A. Sensitivity of Neuroimaging Indicators in Monitoring the Effects of Interferon Gamma Treatment in Friedreich's Ataxia. Front Neurosci 2020;14:872. [PMID: 33162876 DOI: 10.3389/fnins.2020.00872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rodríguez-Pascau L, Britti E, Calap-Quintana P, Dong YN, Vergara C, Delaspre F, Medina-Carbonero M, Tamarit J, Pallardó FV, Gonzalez-Cabo P, Ros J, Lynch DR, Martinell M, Pizcueta P. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia. Neurobiol Dis 2021;148:105162. [PMID: 33171227 DOI: 10.1016/j.nbd.2020.105162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Zesiewicz TA, Hancock J, Ghanekar SD, Kuo SH, Dohse CA, Vega J. Emerging therapies in Friedreich's Ataxia. Expert Rev Neurother 2020;20:1215-28. [PMID: 32909841 DOI: 10.1080/14737175.2020.1821654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Pallardó FV, Pagano G, Rodríguez LR, Gonzalez-Cabo P, Lyakhovich A, Trifuoggi M. Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies. Transl Res 2021;229:135-41. [PMID: 32841735 DOI: 10.1016/j.trsl.2020.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
17 La Rosa P, Petrillo S, Bertini ES, Piemonte F. Oxidative Stress in DNA Repeat Expansion Disorders: A Focus on NRF2 Signaling Involvement. Biomolecules 2020;10:E702. [PMID: 32369911 DOI: 10.3390/biom10050702] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
18 Maio N, Rouault TA. Outlining the Complex Pathway of Mammalian Fe-S Cluster Biogenesis. Trends Biochem Sci 2020;45:411-26. [PMID: 32311335 DOI: 10.1016/j.tibs.2020.02.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
19 La Rosa P, Bertini ES, Piemonte F. The NRF2 Signaling Network Defines Clinical Biomarkers and Therapeutic Opportunity in Friedreich's Ataxia. Int J Mol Sci 2020;21:E916. [PMID: 32019240 DOI: 10.3390/ijms21030916] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
20 Petrillo S, D'Amico J, La Rosa P, Bertini ES, Piemonte F. Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs. Int J Mol Sci 2019;20:E5211. [PMID: 31640150 DOI: 10.3390/ijms20205211] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 7.7] [Reference Citation Analysis]